Prior selection of itraconazole in the treatment of recalcitrant Trichophyton indotineae infection: Real‐world results from retrospective analysis
Mycoses · 2024
DOI: 10.1111/myc.13663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2024. Verfasst von Ge Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Mycology, Institute of Dermatology and Hospital for Skin Disease, Chinese Academy of Medical Sciences & Peking Union Medical Co…. Hauptthemen laut MEDLINE: Itraconazole, Naphthalenes, Tinea. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Key Research and Development Program of China (2022YFC2504804, 2022YFC2504800), Youth Foundation of Beijing Shijitan Hospital affiliated to Capital Medical University (2022- q01), Double-Innovation Doctor Program of Jiangsu province (JSSCBS20221924).
Abstract (Originalsprache)
Background
The number of terbinafine‐resistant Trichophyton indotineae is increasing in recent years while the treatment is still a matter to discuss.
Objectives
To explore the best therapeutic approach, we present real‐world treatment of T. indotineae infection by analysing publicly available data.
Methods
We have reviewed all published articles, mainly including case reports and case series, on the drug‐resistant T. mentagrophytes complex by using the key search terms to search the databases.
Results
We enrolled 25 articles from 14 countries, including 203 times of treatment information for 113 patients. The cure rate of itraconazole 200 mg per day at the fourth, eighth and the twelfth week were 27.27%, 48.48% and 54.55%, respectively, which was significantly higher than terbinafine 250 mg per day (8.77%, 24.56% and 28.07%) and even 500 mg/d terbinafine. Griseofulvin 500–1000 mg for 2–6 months may be effective while fluconazole had no record of successful treatment. Voriconazole and ravuconazole had potential therapeutic efficacy. Topical therapy alone showed limited therapeutic efficacy, but the combination with oral antifungals can be alternative.
Conclusion
Oral itraconazole 200 mg per day for 4–8 weeks was the most effective treatment out of these commonly used antifungal drugs, and can be prior selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Mycology, Institute of Dermatology and Hospital for Skin Disease, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
- Department of Dermatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Xue Kong, Weida Liu, Guanzhao Liang
Förderung
- National Key Research and Development Program of China (2022YFC2504804, 2022YFC2504800)
- Youth Foundation of Beijing Shijitan Hospital affiliated to Capital Medical University (2022- q01)
- Double-Innovation Doctor Program of Jiangsu province (JSSCBS20221924)
- CAMS Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-039)
- National Science and Technology Infrastructure of China (National Pathogen Resource, Center NPRC-32)
- The basic scientific research fund projects of Chinese Academy of Medical Sciences (2021-PT310-006)
Zitieren
APA
Song, G., Kong, X., Li, X., Liu, W., & Liang, G. (2024). Prior selection of itraconazole in the treatment of recalcitrant Trichophyton indotineae infection: Real‐world results from retrospective analysis. Mycoses. https://doi.org/10.1111/myc.13663
Vancouver
Song G, Kong X, Li X, Liu W, Liang G. Prior selection of itraconazole in the treatment of recalcitrant Trichophyton indotineae infection: Real‐world results from retrospective analysis. Mycoses. 2024. doi:10.1111/myc.13663
BibTeX
@article{Song2024,
author = {Song, Ge and Kong, Xue and Li, Xiaofang and Liu, Weida and Liang, Guanzhao},
title = {Prior selection of itraconazole in the treatment of recalcitrant Trichophyton indotineae infection: Real‐world results from retrospective analysis},
journal = {Mycoses},
year = {2024},
doi = {10.1111/myc.13663}
}
EUVIMED